Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Lowers FY '22 PDUFA Fees Due to Hiring, Attrition Concerns

Executive Summary

The agency reissued the user fee notice, saying fewer dollars were needed for new staff.

You may also be interested in...



US FDA’s Marks Was Frustrated About Slow Completion Of 2021 Comirnaty Review

CBER Director Peter Marks told Janet Woodcock in an email that he thought reviewers were treating the BLA for the first fully approved COVID-19 vaccine as a conventional review or learning exercise.

User Fee Carryover Funds Again Decrease Potential Furloughs In US FDA Shutdown Plan

More than 80% of FDA employees would continue working during a government shutdown, which appears unlikely as congressional negotiators announce a ‘framework’ agreement.

US FDA Shutdown Plan Decreases Potential Furloughs Again, Thanks To User Fee Carryover Funds

More than 80% of FDA employees would continue working during a government shutdown, which appears unlikely as congressional negotiators announce a ‘framework’ agreement.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel